GHRP-2 vs IGF-1 LR3.

GHRP-2 (growth hormone-releasing peptide-2; international nonproprietary name pralmorelin; development codes KP-102/GPA-748) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. It belongs to the "classical" growth hormone secretagogue (GHS) family pioneered by Cyril Bowers in the 1980s and is a synthetic agonist of the ghrelin receptor. Unlike GHRH, it is structurally unrelated to any hypothalamic releasing hormone and instead mimics the endogenous gut peptide ghrelin.

IGF-1 LR3 (Long R3 IGF-1) is a synthetic, recombinant analog of human insulin-like growth factor-1. It is an 83-amino-acid polypeptide built from the 70-residue native IGF-1 sequence with two structural changes: a glutamate-to-arginine substitution at position 3 and a 13-residue N-terminal extension peptide. It is produced and sold primarily as a research reagent and as a cell-culture supplement (marketed under names such as LONG R3 IGF-I), not as a licensed human medicine.

GHRP-2 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same Gq/11-coupled receptor targeted by ghrelin, expressed on anterior-pituitary somatotrophs and in the hypothalamus (including the arcuate nucleus). Receptor activation drives phospholipase C signaling, IP3/DAG generation, and intracellular calcium release, evoking pulsatile GH secretion. Because it acts through a pathway distinct from (and synergistic with) GHRH, GHRP-2 and GHRH together produce a markedly larger GH pulse than either alone. Its action on hypothalamic ghrelin-receptor circuits also explains its orexigenic (appetite-stimulating) effect and a degree of off-target activation of the corticotroph and lactotroph axes.

Like native IGF-1, LR3 binds and activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that signals through the PI3K/Akt/mTOR and Ras/MAPK pathways to drive protein synthesis, cell proliferation, and survival. Its distinguishing feature is engineered: the position-3 arginine substitution plus the N-terminal extension dramatically lower its affinity for the six IGF-binding proteins (IGFBPs) that normally sequester circulating IGF-1. Because little of the analog is bound and held by IGFBPs, a much larger fraction remains free to engage IGF-1R, and in animal models its circulating half-life is substantially longer than that of native IGF-1. This same "escape from IGFBP regulation" is why it is favored in mammalian cell culture, where it resists sequestration by cell-secreted binding proteins.

Human pharmacology is well characterized for acute, single-dose use: controlled studies show GHRP-2 reliably triggers a robust GH pulse, and in healthy men it increased subjective hunger and food intake, confirming it behaves as a ghrelin mimetic (Laferrère et al., JCEM 2005). On the strength of acute diagnostic data it is approved in Japan as a single-dose GH-deficiency provocation test, where the GH response separates GH-sufficient from GH-deficient subjects. Critically, the long-term therapeutic program failed: development for treating GH-deficient children/pituitary dwarfism reached Phase II but was not brought to market, in part because the GH response to GHRP-2 is blunted in people with GH deficiency relative to healthy individuals. There are essentially no rigorous long-term human trials demonstrating benefit for body composition, muscle, anti-aging, or performance. Claims in those areas rest on mechanism and short-term hormone changes, not proven clinical outcomes.

Direct evidence for LR3 is overwhelmingly preclinical and in-vitro, not clinical. In a guinea pig study (Conlon et al., J Endocrinol 1995, PMID 7561636), Long R3 IGF-I infusion stimulated organ growth while paradoxically lowering plasma IGF-I, IGF-II, and IGFBP concentrations, illustrating its altered binding-protein behavior in vivo. A mouse study (J Endocrinol 2008, PMID 18577570) reported that long-R3-IGF-I altered mammary signaling and gene expression during prolonged lactation. Analytical work (J Chromatogr B 2003, PMID 12880859) characterized the molecule for bioanalytical detection. There are no controlled human trials demonstrating safety or performance/physique benefits for IGF-1 LR3 specifically; clinical inferences are extrapolated from native IGF-1 (mecasermin) and from receptor pharmacology, which is a meaningful gap because LR3's reduced IGFBP binding changes its tissue exposure relative to the natural hormone.

Documented acute effects in human studies include off-target stimulation of ACTH and cortisol and a transient rise in prolactin, a feature that distinguishes GHRP-2 from the more selective secretagogue ipamorelin (Arvat et al., Peptides 1997). As a ghrelin-receptor agonist it predictably stimulates appetite, and sustained GH/IGF-1 elevation carries the theoretical risks associated with the GH axis (insulin resistance, fluid retention, joint discomfort). The fundamental safety gap is that GHRP-2 has been studied chiefly as a one-time diagnostic agent; the consequences of repeated or chronic non-clinical use, including effects on the HPA axis, glucose metabolism, and any proliferative risk from prolonged IGF-1 elevation, have not been established in controlled long-term human trials. Material sold for "research" use is unregulated and may differ in identity, purity, or sterility from pharmaceutical-grade product.

No human safety dataset exists for IGF-1 LR3 itself; the closest human reference is the FDA-approved native IGF-1 drug mecasermin (Increlex), whose label documents hypoglycemia (including severe, seizure-associated events from its insulin-like action), intracranial hypertension with papilledema, and lymphoid (tonsillar/adenoidal) tissue hypertrophy. Because IGF-1R signaling is mitogenic and anti-apoptotic, a theoretical concern across IGF-1 agonists is the promotion of growth in existing neoplastic tissue, though this has not been quantified for LR3 in humans. LR3's much longer free-ligand exposure could plausibly amplify these effects relative to native IGF-1, but this is unverified. Research-grade material also carries purity, sterility, and mislabeling risks that are not controlled to pharmaceutical standards.

Approved in Japan (marketed by Kaken Pharmaceutical as GHRP Kaken 100) solely as a single-dose diagnostic agent for assessing growth hormone deficiency, making it the only GHS ever granted national regulatory approval, and only for diagnosis, not therapy. It is not FDA-approved for any indication; in the United States and most jurisdictions it is investigational/research-use-only, and it is prohibited in sport under the WADA Prohibited List (S2, growth hormone secretagogues).

IGF-1 LR3 is not approved by the FDA or any major regulator for human use; it is sold for laboratory research and cell-culture manufacturing only. The only FDA-approved IGF-1 product is mecasermin (Increlex), recombinant native IGF-1 indicated for severe primary IGF-1 deficiency, which is a different molecule. IGF-1 and its analogues are prohibited in sport at all times under WADA Prohibited List section S2.